RT Journal Article
SR Electronic
T1 Neutrophil calprotectin identifies severe pulmonary disease in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.06.20093070
DO 10.1101/2020.05.06.20093070
A1 Shi, Hui
A1 Zuo, Yu
A1 Yalavarthi, Srilakshmi
A1 Gockman, Kelsey
A1 Zuo, Melanie
A1 Madison, Jacqueline A.
A1 Blair, Christopher N.
A1 Woods, Robert J.
A1 Lood, Christian
A1 Knight, Jason S.
A1 Kanthi, Yogendra
YR 2020
UL http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093070.abstract
AB Severe cases of coronavirus disease 2019 (COVID-19) are regularly complicated by respiratory failure. While it has been suggested that elevated levels of blood neutrophils associate with worsening oxygenation in COVID-19, it is unknown whether neutrophils are drivers of the thrombo-inflammatory storm or simple bystanders. We now report that patients with COVID-19 (n=96) have markedly elevated levels of the neutrophil activation marker S100A8/A9 (calprotectin) in their blood. Calprotectin tracked with other acute phase reactants including C-reactive protein, D-dimer, ferritin, and absolute neutrophil count, but was superior in identifying patients requiring mechanical ventilation. In longitudinal samples, calprotectin rose as oxygenation worsened. When tested on day 1 or 2 of hospitalization (n=52 patients), calprotectin levels were significantly higher in patients who progressed to severe COVID-19 requiring mechanical ventilation (7805 ± 7585, n=23) as compared to those who remained free of intubation (3123 ± 2990, p=0.0059). In summary, serum calprotectin levels track closely with current and future COVID-19 severity, strongly implicating neutrophils as active perpetuators of inflammation and respiratory compromise in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by a COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center as well as by the A. Alfred Taubman Medical Research Institute.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOnce the manuscript has been published in a peer-reviewed journal, the corresponding author will make all data available upon request.